BRCA1 and triple-negative breast carcinoma: A single-arm prospective study using cisplatin monotherapy in the neoadjuvant setting reported a pathologic complete response rate of 61% among BRCA carriers, most of whom had BRCA1 mutations and triple-negative breast cancer [32].